Evidence map›Paper›PMID 34288600›Full record

ArticleAnnals of clinical and translational neurology2021

Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life.

Leonard L Sokol, Jonathan P Troost, Benzi M Kluger, Allison J Applebaum, Jane S Paulsen, Danny Bega, Samuel Frank, Joshua M Hauser, Nicholas R Boileau, Colin A Depp and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leonard L SokolThe Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0001-5420-9297
Jonathan P TroostMichigan Institute for Clinical and Health Research, University of Michigan, Ann Arbor, Michigan, USA.
Benzi M KlugerDepartments of Neurology and Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Allison J ApplebaumDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jane S PaulsenDepartment of Neurology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Danny BegaThe Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Samuel FrankDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Joshua M HauserDepartment of Medicine, Feinberg School of Medicine and Palliative Care Service, Jesse Brown VA Medical Center, Chicago, Illinois, USA.
Nicholas R BoileauDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.
Colin A DeppDepartment of Psychiatry, University of California, San Diego, California, USA.
David CellaThe Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Noelle E CarlozziDepartment of Physical Medicine and Rehabilitation, University of Michigan, Ann Arbor, Michigan, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Validation of the HD-HRQOL (Huntington disease quality of life measure)R01NS077946 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CARLOZZI, NOELLE E. · 2012 to 2016
$3.2M
Preparing for preventive clinical trials in Huntington's diseaseU01NS105509 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI PAULSEN, JANE S · 2020 to 2025
$2.5M
Statistical disease modeling and clinimetrics to prepare for preventive trials in huntington diseaseU01NS103475 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI PAULSEN, JANE S · 2020 to 2022
$1.7M
Advancing Palliative Care for Older Adults Affected by Neurodegenerative Disease: Parkinsons disease, Alzheimers disease and Related DementiasK02AG062745 · NIA · UNIVERSITY OF ROCHESTER · PI KLUGER, BENZI M · 2020 to 2024
$711k
NCATS NIH HHS UL1 TR000433NCATS NIH HHS UL1 TR002240NCI NIH HHS P30 CA008748NIA NIH HHS K02 AG062745NINDS NIH HHS R01NS0400068NINDS NIH HHS R01 NS077946NINDS NIH HHS U01 NS103475NINDS NIH HHS U01 NS105509
6 · The paper itself

Abstract

objectivePrevious work in Huntington's disease (HD) has shown that a sense of meaning and purpose (M&P) is positively associated with positive affect and well-being (PAW); however, it was unknown whether HD-validated patient-reported outcomes (PROs) influence this association and how M&P impacts PROs in the future. Our study was designed to examine if HD-validated PROs moderate the relationship between M&P and PAW and to evaluate if baseline M&P predicts 12- and 24-month changes in HD-validated PROs.

methodsThis was a longitudinal, multicenter study to develop several PROs (e.g., specific for the physical, emotional, cognitive, and social domains) for people with HD (HDQLIFE). The sample consisted of 322 people with HD (n = 50 prodromal, n = 171 early-stage manifest, and n = 101 late-stage manifest HD). A single, multivariate linear mixed-effects model was performed with PAW as the outcome predicted by main effects for M&P and several moderators (i.e., an HD-validated PRO) and interactions between M&P and a given PRO. Linear-mixed models were also used to assess if baseline M&P predicted HD-validated PROs at 12 and 24 months.

resultsHigher M&P was positively associated with higher PAW regardless of the magnitude of symptom burden, as represented by HD-validated PROs, and independent of disease stage. In our primary analysis, baseline M&P predicted increased PAW and decreased depression, anxiety, anger, emotional/behavioral disruptions, and cognitive decline at 12 and 24 months across all disease stages.

interpretationThese findings parallel those seen in the oncology population and have implications for adapting and developing psychotherapeutic and palliative HD interventions.

Indexed as

AdultAgedFemaleHumansHuntington DiseaseLongitudinal StudiesMaleMiddle AgedQuality of Life

Identifiers

PMID34288600
PMCPMC8351386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.